Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.

Drake JI, Gomez-Arroyo J, Dumur CI, Kraskauskas D, Natarajan R, Bogaard HJ, Fawcett P, Voelkel NF.

Physiol Genomics. 2013 Jun 17;45(12):449-61. doi: 10.1152/physiolgenomics.00166.2012. Epub 2013 Apr 30.

2.

Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension.

Okumura K, Kato H, Honjo O, Breitling S, Kuebler WM, Sun M, Friedberg MK.

J Mol Med (Berl). 2015 Jun;93(6):663-74. doi: 10.1007/s00109-015-1251-9. Epub 2015 Jan 18.

PMID:
25595602
3.

Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.

Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, Voelkel NF.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):652-60. doi: 10.1164/rccm.201003-0335OC. Epub 2010 May 27.

PMID:
20508210
4.

Identification of gene signatures regulated by carvedilol in mouse heart.

Teoh JP, Park KM, Broskova Z, Jimenez FR, Bayoumi AS, Archer K, Su H, Johnson J, Weintraub NL, Tang Y, Kim IM.

Physiol Genomics. 2015 Sep;47(9):376-85. doi: 10.1152/physiolgenomics.00028.2015. Epub 2015 Jul 7.

5.

Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension.

Xie YP, Chen B, Sanders P, Guo A, Li Y, Zimmerman K, Wang LC, Weiss RM, Grumbach IM, Anderson ME, Song LS.

Hypertension. 2012 Feb;59(2):355-62. doi: 10.1161/HYPERTENSIONAHA.111.180968. Epub 2011 Dec 27.

6.

Salubrinal attenuates right ventricular hypertrophy and dysfunction in hypoxic pulmonary hypertension of rats.

He YY, Liu CL, Li X, Li RJ, Wang LL, He KL.

Vascul Pharmacol. 2016 Dec;87:190-198. doi: 10.1016/j.vph.2016.09.009. Epub 2016 Sep 24.

PMID:
27678416
7.

Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension.

Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, Chalfant CE, Bigbee J, Abbate A, Lesnefsky EJ, Bogaard HJ, Voelkel NF.

Circ Heart Fail. 2013 Jan;6(1):136-44. doi: 10.1161/CIRCHEARTFAILURE.111.966127. Epub 2012 Nov 14.

8.

Clinical symptoms of right ventricular failure in experimental chronic pressure load are associated with progressive diastolic dysfunction.

Borgdorff MA, Koop AM, Bloks VW, Dickinson MG, Steendijk P, Sillje HH, van Wiechen MP, Berger RM, Bartelds B.

J Mol Cell Cardiol. 2015 Feb;79:244-53. doi: 10.1016/j.yjmcc.2014.11.024. Epub 2014 Dec 5.

PMID:
25486580
9.

Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure?

Balestra GM, Mik EG, Eerbeek O, Specht PA, van der Laarse WJ, Zuurbier CJ.

Respir Res. 2015 Feb 3;16:6. doi: 10.1186/s12931-015-0178-6.

10.

Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure.

Rajagopalan V, Zhao M, Reddy S, Fajardo G, Wang X, Dewey S, Gomes AV, Bernstein D.

Am J Physiol Heart Circ Physiol. 2013 Aug 15;305(4):H551-62. doi: 10.1152/ajpheart.00771.2012. Epub 2013 May 31.

11.

Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia.

Tual L, Morel OE, Favret F, Fouillit M, Guernier C, Buvry A, Germain L, Dhonneur G, Bernaudin JF, Richalet JP.

Pflugers Arch. 2006 Jul;452(4):371-9. Epub 2006 Apr 26.

PMID:
16639551
12.

A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle.

Giardini A, Lovato L, Donti A, Formigari R, Gargiulo G, Picchio FM, Fattori R.

Int J Cardiol. 2007 Jan 8;114(2):241-6. doi: 10.1016/j.ijcard.2006.01.048.

PMID:
21882492
13.

MicroRNA-140 is elevated and mitofusin-1 is downregulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension.

Joshi SR, Dhagia V, Gairhe S, Edwards JG, McMurtry IF, Gupte SA.

Am J Physiol Heart Circ Physiol. 2016 Sep 1;311(3):H689-98. doi: 10.1152/ajpheart.00264.2016. Epub 2016 Jul 15.

15.

Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart.

Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY.

Clin Exp Pharmacol Physiol. 2005 Jul;32(7):553-60.

PMID:
16026515
16.
17.

Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.

Barone FC, Willette RN, Nelson AH, Ohlstein EH, Brooks DP, Coatney RW.

Pharmacology. 2007;80(2-3):166-76. Epub 2007 Jun 4.

PMID:
17551266
18.

Transcriptional profile of right ventricular tissue during acute pulmonary embolism in rats.

Zagorski J, Sanapareddy N, Gellar MA, Kline JA, Watts JA.

Physiol Genomics. 2008 Jun 12;34(1):101-11. doi: 10.1152/physiolgenomics.00261.2007. Epub 2008 Apr 22.

19.

Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis.

Sun XQ, Zhang R, Zhang HD, Yuan P, Wang XJ, Zhao QH, Wang L, Jiang R, Jan Bogaard H, Jing ZC.

Hypertens Res. 2016 May;39(5):302-11. doi: 10.1038/hr.2015.153. Epub 2016 Jan 14.

PMID:
26763846
20.

Treatment of group I pulmonary arterial hypertension with carvedilol is safe.

Grinnan D, Bogaard HJ, Grizzard J, Van Tassell B, Abbate A, DeWilde C, Priday A, Voelkel NF.

Am J Respir Crit Care Med. 2014 Jun 15;189(12):1562-4. doi: 10.1164/rccm.201311-2025LE. No abstract available.

PMID:
24930531

Supplemental Content

Support Center